MIDATECH PHARMA
R&D

Midatech's two platform technologies are designed to enable targeted delivery and sustained release respectively of existing therapeutic drugs to the ‘right place’ at the ‘right time’. The first of these platforms is a Gold Nanoparticle Technology Platform (GNPs) that are developed to improve key parameters of existing and new drugs, target individual cell types with specific targeting agents and deliver a payload in the cell, while ensuring this can be achieved safely. GNP technology represents amongst the latest generation of nanomedicine and the fastest growing sector within the nanomedicine market. The second of these platforms is a Microsphere Sustained Release Technology Platform (SR) that achieves consistent and precise encapsulation of active drug compounds within polymer microspheres. The microspheres are designed to release the active drug compound into the body in a highly controlled manner over a prolonged period of time, from a number of weeks to six months and potentially longer. Sustained release technology provides the added capacity to sustain the optimal range of drug concentrations, which has wide medical applicability with diverse pharmaceutically active molecules.

R&D
R&D

Midatech's two platform technologies are designed to enable targeted delivery and sustained release respectively of existing therapeutic drugs to the ‘right place’ at the ‘right time’. The first of these platforms is a Gold Nanoparticle Technology Platform (GNPs) that are developed to improve key parameters of existing and new drugs, target individual cell types with specific targeting agents and deliver a payload in the cell, while ensuring this can be achieved safely. GNP technology represents amongst the latest generation of nanomedicine and the fastest growing sector within the nanomedicine market. The second of these platforms is a Microsphere Sustained Release Technology Platform (SR) that achieves consistent and precise encapsulation of active drug compounds within polymer microspheres. The microspheres are designed to release the active drug compound into the body in a highly controlled manner over a prolonged period of time, from a number of weeks to six months and potentially longer. Sustained release technology provides the added capacity to sustain the optimal range of drug concentrations, which has wide medical applicability with diverse pharmaceutically active molecules.

© Copyright 2017 Midatech Pharma PLC